Last 7 days
-2.6%
Last 30 days
0.9%
Last 90 days
-15.8%
Trailing 12 Months
-34.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
HCA | 73.0B | 60.9B | -4.91% | 25.24% | 12.73 | 1.2 | 1.94% | -15.77% |
LH | 20.7B | 14.8B | -2.77% | -13.32% | 16.22 | 1.39 | -6.96% | -52.35% |
DGX | 15.0B | 9.6B | -8.90% | -4.59% | 18.89 | 1.56 | -10.08% | -57.84% |
MID-CAP | ||||||||
UHS | 9.9B | 13.6B | -10.37% | 3.84% | 14.64 | 0.74 | 5.04% | -26.87% |
CHE | 8.1B | 2.2B | -3.35% | 8.33% | 33.85 | 3.75 | 1.03% | -10.38% |
LHCG | 5.2B | 2.3B | 3.17% | 35.63% | 86.23 | 2.28 | 2.85% | -58.05% |
ENSG | 5.0B | 3.2B | -11.17% | 9.89% | 21.14 | 1.55 | 17.88% | 19.62% |
AMN | 3.9B | 4.8B | 11.84% | 2.65% | 10.12 | 0.8 | 3.57% | -4.88% |
GH | 2.9B | 482.2M | 34.10% | -27.10% | -4.41 | 5.98 | 23.29% | -70.12% |
AMED | 2.5B | 2.2B | 0.86% | -34.14% | 22.43 | 1.13 | 0.55% | -41.23% |
SMALL-CAP | ||||||||
RDNT | 1.7B | 1.5B | 6.01% | 44.82% | -126.07 | 1.14 | 10.24% | -173.11% |
ADUS | 1.4B | 976.1M | -21.09% | 3.91% | 28.65 | 1.47 | 10.19% | 12.37% |
NHC | 919.4M | 1.1B | 3.90% | -11.21% | 51.63 | 0.85 | -2.36% | -86.62% |
VMD | 394.4M | 146.1M | -12.69% | 63.35% | 63.38 | 2.84 | 20.87% | -35.06% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 0.5% | 2,234 | 2,223 | 2,220 | 2,216 | 2,222 |
S&GA Expenses | 1.7% | 736 | 724 | - | - | - |
Costs and Expenses | 0.8% | 2,059 | 2,042 | 2,038 | 2,015 | 1,996 |
EBITDA | -3.0% | 207 | 214 | 235 | 298 | - |
EBITDA Margin | -3.1% | 0.09* | 0.10* | 0.11* | 0.13* | - |
Earnings Before Taxes | -5.6% | 151 | 160 | 166 | 187 | 256 |
EBT Margin | -3.5% | 0.07* | 0.07* | 0.08* | 0.12* | - |
Interest Expenses | 19.5% | 27.00 | 22.00 | 19.00 | 17.00 | 11.00 |
Net Income | -5.4% | 112 | 119 | 121 | 140 | 191 |
Net Income Margin | -2.0% | 0.05* | 0.05* | 0.06* | 0.09* | - |
Free Cahsflow | 38.0% | 127 | 92.00 | 167 | 178 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -1.5% | 1,947 | 1,976 | 1,982 | 2,001 | 1,908 |
Current Assets | 4.3% | 406 | 389 | 389 | 395 | 392 |
Cash Equivalents | 70.4% | 69.00 | 41.00 | 18.00 | 27.00 | 68.00 |
Net PPE | 108.5% | 33.00 | 16.00 | 17.00 | 18.00 | 17.00 |
Goodwill | -3.3% | 1,245 | 1,287 | 1,285 | 1,290 | 9.00 |
Liabilities | -6.4% | 814 | 870 | 913 | 962 | 888 |
Current Liabilities | -0.7% | 353 | 356 | 367 | 427 | 380 |
Long Term Debt | -11.0% | 373 | 419 | 443 | 442 | 429 |
Shareholder's Equity | 7.8% | 1,133 | 1,052 | 1,016 | 1,039 | 1,021 |
Retained Earnings | 3.3% | 783 | 758 | 726 | 700 | 671 |
Additional Paid-In Capital | 0.5% | 759 | 755 | 751 | 743 | 737 |
Accumulated Depreciation | 3.7% | 105 | 101 | 102 | 100 | 99.00 |
Shares Outstanding | 0.1% | 33.00 | 33.00 | 32.00 | 32.00 | 33.00 |
Minority Interest | -1.4% | 54.00 | 55.00 | 54.00 | 53.00 | 54.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -17.0% | 111 | 133 | 98.00 | 173 | 184 |
Share Based Compensation | -24.6% | 12.00 | 17.00 | 22.00 | 23.00 | 24.00 |
Cashflow From Investing | 65.6% | -32.51 | -94.49 | -104 | -367 | -296 |
Cashflow From Financing | -162.6% | -79.92 | -30.43 | -90.03 | 151 | 105 |
Buy Backs | -46.4% | 17.00 | 32.00 | 43.00 | 27.00 | - |
73.1%
36.5%
33.5%
Y-axis is the maximum loss one would have experienced if Amedisys was unfortunately bought at previous high price.
19.7%
6.2%
0.7%
-25.7%
FIve years rolling returns for Amedisys.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | Capital Impact Advisors, LLC | reduced | -33.37 | -233,989 | 332,078 | 0.41% |
2023-05-23 | Front Row Advisors LLC | unchanged | - | - | 2,000 | -% |
2023-05-23 | Seaport Global Advisors, LLC | added | 12.37 | -2,017 | 186,449 | 0.59% |
2023-05-23 | Toroso Investments, LLC | new | - | 478,000 | 478,000 | 0.01% |
2023-05-22 | FDx Advisors, Inc. | unchanged | - | - | 231,000 | 0.01% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -24.99 | -30,716,200 | 59,729,800 | 0.02% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | added | 8.57 | -181,000 | 3,918,000 | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 13.48 | -139,000 | 146,881,000 | 0.02% |
2023-05-17 | Sunbelt Securities, Inc. | new | - | 5,823 | 5,823 | -% |
2023-05-17 | Advisory Services Network, LLC | unchanged | - | -7,702 | 56,708 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
May 18, 2023 | flynn james e | 5.51% | 1,794,000 | SC 13G | |
Feb 14, 2023 | ameriprise financial inc | 3.39% | 1,100,719 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.63% | 3,128,416 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 8.63% | 2,802,831 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 12.6% | 4,106,566 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 12.6% | 4,106,566 | SC 13G | |
Jan 06, 2023 | jpmorgan chase & co | 5.4% | 1,763,327 | SC 13G | |
Feb 14, 2022 | ameriprise financial inc | 5.35% | 1,742,916 | SC 13G | |
Feb 09, 2022 | vanguard group inc | 9.69% | 3,158,777 | SC 13G/A | |
Feb 04, 2022 | wellington management group llp | 5.56% | 1,812,411 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 57.59 -25.51% | 70.52 -8.78% | 90.91 17.59% | 121.81 57.56% | 139.69 80.69% |
Current Inflation | 53.76 -30.46% | 64.93 -16.01% | 82.14 6.25% | 108.07 39.79% | 123.02 59.13% |
Very High Inflation | 48.98 -36.64% | 58.09 -24.86% | 71.66 -7.31% | 92.01 19.01% | 103.69 34.12% |
Date Filed | Form Type | Document | |
---|---|---|---|
May 26, 2023 | 425 | Prospectus Filed | |
May 26, 2023 | 425 | Prospectus Filed | |
May 18, 2023 | 425 | Prospectus Filed | |
May 18, 2023 | SC 13G | Major Ownership Report | |
May 17, 2023 | 425 | Prospectus Filed | |
May 15, 2023 | 425 | Prospectus Filed | |
May 15, 2023 | 425 | Prospectus Filed | |
May 15, 2023 | 425 | Prospectus Filed | |
May 15, 2023 | 425 | Prospectus Filed | |
May 10, 2023 | 425 | Prospectus Filed |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-03 | Samuels Ivanetta Davis | acquired | - | - | 1,941 | - |
2023-05-03 | Klapstein Julie D | acquired | - | - | 1,941 | - |
2023-05-03 | PERKINS BRUCE D | acquired | - | - | 1,941 | - |
2023-05-03 | Rideout Jeffrey A | acquired | - | - | 1,941 | - |
2023-05-03 | CAPPS VICKIE L | acquired | - | - | 1,941 | - |
2023-05-03 | Coye Molly Joel | acquired | - | - | 1,941 | - |
2023-05-03 | Kline Teresa L. | acquired | - | - | 1,941 | - |
2023-04-12 | Ashworth Richard M | acquired | - | - | 46,982 | president and ceo |
2023-04-10 | Kusserow Paul B. K. | sold (taxes) | -1,282,350 | 78.88 | -16,257 | - |
2023-03-03 | North Michael Paul | sold | -510,628 | 86.43 | -5,908 | chief information officer |
CONSOLIDATED INCOME STATEMENT - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
Net service revenue | $ 556,389 | $ 545,257 |
Cost of service, inclusive of depreciation | 315,010 | 304,820 |
General and administrative expenses: | ||
Salaries and benefits | 126,339 | 123,480 |
Non-cash compensation | 3,273 | 7,347 |
Depreciation and amortization | 4,443 | 8,008 |
Other | 64,945 | 53,640 |
Total operating expenses | 514,010 | 497,295 |
Operating income | 42,379 | 47,962 |
Other income (expense): | ||
Interest income | 406 | 13 |
Interest expense | (7,517) | (3,173) |
Equity in earnings (loss) from equity method investments | 123 | (1,403) |
Miscellaneous, net | (682) | 333 |
Total other expense, net | (7,670) | (4,230) |
Income before income taxes | 34,709 | 43,732 |
Income tax expense | (9,800) | (12,019) |
Net income | 24,909 | 31,713 |
Net loss (income) attributable to noncontrolling interests | 337 | (42) |
Net income attributable to Amedisys, Inc. | $ 25,246 | $ 31,671 |
Basic earnings per common share: | ||
Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share) | $ 0.78 | $ 0.97 |
Weighted average shares outstanding, basic (shares) | 32,558 | 32,555 |
Diluted earnings per common share: | ||
Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share) | $ 0.77 | $ 0.97 |
Weighted average shares outstanding, diluted (shares) | 32,643 | 32,766 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 49,436 | $ 40,540 |
Restricted cash | 19,664 | 13,593 |
Patient accounts receivable | 294,122 | 296,785 |
Prepaid expenses | 18,754 | 11,628 |
Other current assets | 23,581 | 26,415 |
Total current assets | 405,557 | 388,961 |
Property and equipment, net of accumulated depreciation of $105,183 and $101,364 | 33,353 | 16,026 |
Operating lease right of use assets | 85,211 | 102,856 |
Goodwill | 1,244,679 | 1,287,399 |
Intangible assets, net of accumulated amortization of $16,071 and $14,604 | 99,929 | 101,167 |
Other assets | 78,230 | 79,836 |
Total assets | 1,946,959 | 1,976,245 |
Current liabilities: | ||
Accounts payable | 40,017 | 43,735 |
Payroll and employee benefits | 122,723 | 125,387 |
Accrued expenses | 137,899 | 137,390 |
Current portion of long-term obligations | 26,958 | 15,496 |
Current portion of operating lease liabilities | 25,453 | 33,521 |
Total current liabilities | 353,050 | 355,529 |
Long-term obligations, less current portion | 373,202 | 419,420 |
Operating lease liabilities, less current portion | 59,826 | 69,504 |
Deferred income tax liabilities | 22,752 | 20,411 |
Other long-term obligations | 4,781 | 4,808 |
Total liabilities | 813,611 | 869,672 |
Commitments and Contingencies—Note 7 | ||
Equity: | ||
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding | 0 | 0 |
Common stock, $0.001 par value, 60,000,000 shares authorized; 37,938,354 and 37,891,186 shares issued; 32,544,145 and 32,511,465 shares outstanding | 38 | 38 |
Additional paid-in capital | 758,669 | 755,063 |
Treasury stock, at cost, 5,394,209 and 5,379,721 shares of common stock | (462,508) | (461,200) |
Retained earnings | 782,918 | 757,672 |
Total Amedisys, Inc. stockholders’ equity | 1,079,117 | 1,051,573 |
Noncontrolling interests | 54,231 | 55,000 |
Total equity | 1,133,348 | 1,106,573 |
Total liabilities and equity | $ 1,946,959 | $ 1,976,245 |